Best Reits this March 2026

American Tower (AMT) stands out as a top cell tower REIT, showcasing robust earnings and promising growth potential. With a dividend yield of nearly 3.87%, it's an attractive option for investors seeking reliable income, despite recent returns reflecting a decline of 9.24% over the past year. Analysts maintain a favorable outlook, with a median 12-month price target of $210, supported by ratings of Buy from UBS and Overweight from Morgan Stanley.

AMT is expected to grow its AFFO per share from $10.68 in 2025 to $13.82 by 2030, representing a 30% increase over five years.

Crown Castle International (CCI) stands out as a specialty REIT with a robust portfolio of 40,000 wireless towers in the U.S., currently trading 27% below its fair value. With a dividend yield of 4.71%, it promises reliable income, although it has faced a challenging year with a 1-year return of -5.84% and a steep 5-year decline of -39.23%. Analysts have issued a mixed outlook, setting a median 12-month price target of $106.50, indicating potential upside amidst its current undervaluation.

Crown Castle is expected to see normalized revenue growth of 4-5% post-2026, with improving dividend coverage and an estimated 2027 AFFO per share of $4.95–$5.19, resulting in a dividend yield of around 5%.

Federal Realty Investment Trust (FRT) stands out as a premium retail REIT, boasting high-quality shopping centers in prime metropolitan areas. With a solid dividend yield of 4.06% and a history of 21 consecutive years of dividend increases, it remains a compelling choice for investors seeking reliable income. Analysts maintain a consensus rating of Hold, with a median 12-month price target of $109, reflecting a balanced outlook for future growth.

FRT has a consensus rating of Hold from 13 analysts, with 8% recommending Strong Buy, 38% Buy, and 54% suggesting Hold.

The average one-year price target for FRT, based on 18 analysts, is $113.06, with a high estimate of $127.00 and a low estimate of $103.00.

FRT pays quarterly dividends and has increased them for 21 consecutive years, indicating strong financial stability.

Healthpeak Properties (DOC) is a healthcare REIT positioned to capitalize on sector rebounds and declining interest rates, making it an attractive choice for income-focused investors. Despite a challenging performance, reflected in a 1-year return of -14.26% and a 5-year return of -40.23%, the stock offers a robust dividend yield of 6.39%. Analysts have a median price target of $17.50, indicating potential upside, with ratings ranging from “Hold” to “Outperform” across various firms.

Doximity, Inc. (DOCS) shares have decreased by $0.57, or 2.27%, closing at $24.53.

On October 29, 2023, Physicians Realty Trust entered into a merger agreement with Healthpeak Properties Inc., where each share of Physicians Realty Trust will be converted into 0.674 shares of Healthpeak Properties Inc.

EastGroup Properties (EGP) focuses on industrial real estate, particularly flex warehouses in thriving Sunbelt markets, boasting an impressive occupancy rate of 96.5%. With a solid dividend yield of 3.31% and strong returns—5.67% over the past year and 45.77% over the last five years—EGP presents an attractive option for investors seeking reliable income and growth potential. Analysts have a consensus Buy rating with a median price target of $200, indicating a potential upside from its recent closing price.

EastGroup Properties (EGP) has a consensus rating of Buy from 13 analysts, with 23% recommending Strong Buy, 46% recommending Buy, and 31% suggesting Hold.

Analysts forecast EGP's price to range from $172.00 to $230.00, indicating an average target that suggests a 6.22% increase from its last closing price of $190.64.

Analysts set the price target for EGY at $9.28, with a maximum estimate of $11.50 and a minimum estimate of $7.30.

Prologis (PLD) stands out as a leading logistics REIT, with a strong presence in key U.S. markets, positioning it well to benefit from the growing demand for e-commerce. With a solid dividend yield of 2.91% and impressive 5-year returns of 46.71%, PLD offers a reliable income stream backed by its history of consistent dividend increases over 13 years. Analysts maintain a median 12-month price target of $135.00, reflecting a cautiously optimistic outlook amid its current market positioning.

PLD has a Growth Score of F, indicating potential underperformance, but its Momentum Score of B suggests it may appeal to momentum investors.

PLD is rated #3 (Hold) on the Zacks Rank, with a revised earnings estimate of $6.12 for fiscal 2026, reflecting a 2.5% average earnings surprise.

PLD has a strong dividend safety record, having consistently increased its dividend payout for 13 consecutive years.

Pine Labs Ltd. has an average price target of 225, suggesting a potential upside of 7.87% from its current price of 208.58.